(Q44414803)

2 December 2017

0 references

Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine (English)

1 reference

2 December 2017

Zuzana Walker

9

0 references

Javier Arbizu

object named as

Javier Arbizu

2

0 references

Flavio Nobili

object named as

Flavio Nobili

5

0 references

Klaus Tatsch

8

object named as

Klaus Tatsch

1 reference

2 December 2017

6

Pierre Payoux

1 reference

2 December 2017

Jan Booij

1

1 reference

2 December 2017

Jacques Darcourt

3

1 reference

2 December 2017

Swen Hesse

4

1 reference

2 December 2017

Sabina Pappatà

7

1 reference

2 December 2017

Marco Pagani

10

1 reference

2 December 2017

publication date

1 July 2013

1 reference

2 December 2017

number of pages

4

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

2 December 2017

volume

40

1 reference

2 December 2017

issue

7

1 reference

2 December 2017

page(s)

1122-1125

1 reference

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Imaging amyloid deposition in Lewy body diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

In vivo imaging of astrocytosis in Alzheimer's disease: an ¹¹C-L-deuteriodeprenyl and PIB PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

A European multicentre PET study of fibrillar amyloid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

In vivo amyloid imaging with PET in frontotemporal dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

[(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

SNMMI/EANM guideline for guideline development 6.0.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2415-X

Alzheimer disease: Aβ-independent processes-rethinking preclinical AD.

21 January 2018

1 reference

12 December 2020

ACCF proposed method for evaluating the appropriateness of cardiovascular imaging

1 reference

12 December 2020

Relationship between atrophy and beta-amyloid deposition in Alzheimer disease

1 reference

12 December 2020

Impact of molecular imaging on the diagnostic process in a memory clinic

1 reference

12 December 2020

10.1007/S00259-013-2415-X

Identifiers

DOI

1 reference

2 December 2017

1 reference